Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 33.66
+9.86 (41.43%)
Aug 20, 2026, 4:09 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 11.83 billion as of August 20, 2026. Its market cap has decreased by -53.37% in one year.
Market Cap
11.83B
Enterprise Value
11.78B
Revenue
2.78B
Ranking
n/a
PE Ratio
n/a
Stock Price
33.66
ChartMarket Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 11.83B, a decrease of -42.68%. That is a compound annual growth rate of -9.05%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 20, 2026 | 11.83B | -9.45% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ascletis Pharma | 10.38B |
| Shaanxi Micot Pharmaceutical Technology | 10.15B |
| TenNor Therapeutics (Suzhou) | 9.31B |
| Suzhou Ribo Life Science | 8.84B |
| CARsgen Therapeutics Holdings | 8.74B |
| LongBio Pharma (Suzhou) | 8.51B |
| CStone Pharmaceuticals | 8.18B |
| Alphamab Oncology | 7.81B |